The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands.
Identifieur interne : 000069 ( Main/Exploration ); précédent : 000068; suivant : 000070The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands.
Auteurs : Marcus Richard Keogh-Brown [Royaume-Uni] ; Richard D. Smith ; John W. Edmunds ; Philippe BeutelsSource :
- The European journal of health economics : HEPAC : health economics in prevention and care [ 1618-7601 ] ; 2010.
Descripteurs français
- KwdFr :
- Antiviraux (usage thérapeutique), Antiviraux (économie), Belgique (épidémiologie), Flambées de maladies (), Flambées de maladies (économie), France (épidémiologie), Grippe humaine (mortalité), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains, Internationalité, Modèles économiques, Pays-Bas (épidémiologie), Politique de santé (tendances), Politique de santé (économie), Royaume-Uni (épidémiologie), Santé publique (), Santé publique (économie), Vaccination (), Vaccination (économie), Économie ().
- MESH :
- mortalité : Grippe humaine.
- tendances : Politique de santé.
- usage thérapeutique : Antiviraux.
- économie : Antiviraux, Flambées de maladies, Grippe humaine, Politique de santé, Santé publique, Vaccination.
- épidémiologie : Belgique, France, Grippe humaine, Pays-Bas, Royaume-Uni.
- Flambées de maladies, Humains, Internationalité, Modèles économiques, Santé publique, Vaccination, Économie.
English descriptors
- KwdEn :
- Antiviral Agents (economics), Antiviral Agents (therapeutic use), Belgium (epidemiology), Disease Outbreaks (economics), Disease Outbreaks (prevention & control), Disease Outbreaks (statistics & numerical data), Economics (statistics & numerical data), France (epidemiology), Health Policy (economics), Health Policy (trends), Humans, Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (mortality), Internationality, Models, Economic, Netherlands (epidemiology), Public Health (economics), Public Health (statistics & numerical data), United Kingdom (epidemiology), Vaccination (economics), Vaccination (statistics & numerical data).
- MESH :
- chemical , economics : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- economics : Disease Outbreaks, Health Policy, Influenza, Human, Public Health, Vaccination.
- epidemiology : Belgium, France, Influenza, Human, Netherlands, United Kingdom.
- mortality : Influenza, Human.
- prevention & control : Disease Outbreaks.
- statistics & numerical data : Disease Outbreaks, Economics, Public Health, Vaccination.
- trends : Health Policy.
- Humans, Internationality, Models, Economic.
Abstract
The 2003 outbreak of severe acute respiratory syndrome (SARS) showed that infectious disease outbreaks can have notable macroeconomic impacts. The current H1N1 and potential H5N1 flu pandemics could have a much greater impact. Using a multi-sector single country computable general equilibrium model of the United Kingdom, France, Belgium and The Netherlands, together with disease scenarios of varying severity, we examine the potential economic cost of a modern pandemic. Policies of school closure, vaccination and antivirals, together with prophylactic absence from work are evaluated and their cost impacts are estimated. Results suggest GDP losses from the disease of approximately 0.5-2% but school closure and prophylactic absenteeism more than triples these effects. Increasing school closures from 4 weeks at the peak to entire pandemic closure almost doubles the economic cost, but antivirals and vaccinations seem worthwhile. Careful planning is therefore important to ensure expensive policies to mitigate the pandemic are effective in minimising illness and deaths.
DOI: 10.1007/s10198-009-0210-1
PubMed: 19997956
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands.</title><author><name sortKey="Keogh Brown, Marcus Richard" sort="Keogh Brown, Marcus Richard" uniqKey="Keogh Brown M" first="Marcus Richard" last="Keogh-Brown">Marcus Richard Keogh-Brown</name><affiliation wicri:level="3"><nlm:affiliation>Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK. Marcus.keogh-brown@lshtm.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Smith, Richard D" sort="Smith, Richard D" uniqKey="Smith R" first="Richard D" last="Smith">Richard D. Smith</name></author><author><name sortKey="Edmunds, John W" sort="Edmunds, John W" uniqKey="Edmunds J" first="John W" last="Edmunds">John W. Edmunds</name></author><author><name sortKey="Beutels, Philippe" sort="Beutels, Philippe" uniqKey="Beutels P" first="Philippe" last="Beutels">Philippe Beutels</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:19997956</idno><idno type="pmid">19997956</idno><idno type="doi">10.1007/s10198-009-0210-1</idno><idno type="wicri:Area/Main/Corpus">000079</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000079</idno><idno type="wicri:Area/Main/Curation">000079</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000079</idno><idno type="wicri:Area/Main/Exploration">000079</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands.</title><author><name sortKey="Keogh Brown, Marcus Richard" sort="Keogh Brown, Marcus Richard" uniqKey="Keogh Brown M" first="Marcus Richard" last="Keogh-Brown">Marcus Richard Keogh-Brown</name><affiliation wicri:level="3"><nlm:affiliation>Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK. Marcus.keogh-brown@lshtm.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Smith, Richard D" sort="Smith, Richard D" uniqKey="Smith R" first="Richard D" last="Smith">Richard D. Smith</name></author><author><name sortKey="Edmunds, John W" sort="Edmunds, John W" uniqKey="Edmunds J" first="John W" last="Edmunds">John W. Edmunds</name></author><author><name sortKey="Beutels, Philippe" sort="Beutels, Philippe" uniqKey="Beutels P" first="Philippe" last="Beutels">Philippe Beutels</name></author></analytic><series><title level="j">The European journal of health economics : HEPAC : health economics in prevention and care</title><idno type="eISSN">1618-7601</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (economics)</term><term>Antiviral Agents (therapeutic use)</term><term>Belgium (epidemiology)</term><term>Disease Outbreaks (economics)</term><term>Disease Outbreaks (prevention & control)</term><term>Disease Outbreaks (statistics & numerical data)</term><term>Economics (statistics & numerical data)</term><term>France (epidemiology)</term><term>Health Policy (economics)</term><term>Health Policy (trends)</term><term>Humans</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (mortality)</term><term>Internationality</term><term>Models, Economic</term><term>Netherlands (epidemiology)</term><term>Public Health (economics)</term><term>Public Health (statistics & numerical data)</term><term>United Kingdom (epidemiology)</term><term>Vaccination (economics)</term><term>Vaccination (statistics & numerical data)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Antiviraux (économie)</term><term>Belgique (épidémiologie)</term><term>Flambées de maladies ()</term><term>Flambées de maladies (économie)</term><term>France (épidémiologie)</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Internationalité</term><term>Modèles économiques</term><term>Pays-Bas (épidémiologie)</term><term>Politique de santé (tendances)</term><term>Politique de santé (économie)</term><term>Royaume-Uni (épidémiologie)</term><term>Santé publique ()</term><term>Santé publique (économie)</term><term>Vaccination ()</term><term>Vaccination (économie)</term><term>Économie ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term><term>Health Policy</term><term>Influenza, Human</term><term>Public Health</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Belgium</term><term>France</term><term>Influenza, Human</term><term>Netherlands</term><term>United Kingdom</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Disease Outbreaks</term><term>Economics</term><term>Public Health</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Politique de santé</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Health Policy</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antiviraux</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Politique de santé</term><term>Santé publique</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Belgique</term><term>France</term><term>Grippe humaine</term><term>Pays-Bas</term><term>Royaume-Uni</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Internationality</term><term>Models, Economic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Flambées de maladies</term><term>Humains</term><term>Internationalité</term><term>Modèles économiques</term><term>Santé publique</term><term>Vaccination</term><term>Économie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 2003 outbreak of severe acute respiratory syndrome (SARS) showed that infectious disease outbreaks can have notable macroeconomic impacts. The current H1N1 and potential H5N1 flu pandemics could have a much greater impact. Using a multi-sector single country computable general equilibrium model of the United Kingdom, France, Belgium and The Netherlands, together with disease scenarios of varying severity, we examine the potential economic cost of a modern pandemic. Policies of school closure, vaccination and antivirals, together with prophylactic absence from work are evaluated and their cost impacts are estimated. Results suggest GDP losses from the disease of approximately 0.5-2% but school closure and prophylactic absenteeism more than triples these effects. Increasing school closures from 4 weeks at the peak to entire pandemic closure almost doubles the economic cost, but antivirals and vaccinations seem worthwhile. Careful planning is therefore important to ensure expensive policies to mitigate the pandemic are effective in minimising illness and deaths.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19997956</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-7601</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The European journal of health economics : HEPAC : health economics in prevention and care</Title><ISOAbbreviation>Eur J Health Econ</ISOAbbreviation></Journal><ArticleTitle>The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands.</ArticleTitle><Pagination><MedlinePgn>543-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10198-009-0210-1</ELocationID><Abstract><AbstractText>The 2003 outbreak of severe acute respiratory syndrome (SARS) showed that infectious disease outbreaks can have notable macroeconomic impacts. The current H1N1 and potential H5N1 flu pandemics could have a much greater impact. Using a multi-sector single country computable general equilibrium model of the United Kingdom, France, Belgium and The Netherlands, together with disease scenarios of varying severity, we examine the potential economic cost of a modern pandemic. Policies of school closure, vaccination and antivirals, together with prophylactic absence from work are evaluated and their cost impacts are estimated. Results suggest GDP losses from the disease of approximately 0.5-2% but school closure and prophylactic absenteeism more than triples these effects. Increasing school closures from 4 weeks at the peak to entire pandemic closure almost doubles the economic cost, but antivirals and vaccinations seem worthwhile. Careful planning is therefore important to ensure expensive policies to mitigate the pandemic are effective in minimising illness and deaths.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keogh-Brown</LastName><ForeName>Marcus Richard</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK. Marcus.keogh-brown@lshtm.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Edmunds</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Beutels</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Health Econ</MedlineTA><NlmUniqueID>101134867</NlmUniqueID><ISSNLinking>1618-7598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N">Belgium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004467" MajorTopicYN="N">Economics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19997956</ArticleId><ArticleId IdType="doi">10.1007/s10198-009-0210-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1970 Oct;92(4):240-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5458216</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Econ. 2008 Nov;17(11):1317-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18246542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jul 27;442(7101):448-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16642006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Apr 29;367(9520):1405-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16650650</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J. 1958 Nov 29;2(5108):1316-8</Citation><ArticleIdList><ArticleId IdType="pubmed">13596596</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Econ. 2009 Jan;28(1):221-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19062116</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Econ. 2005 Nov;24(6):1055-75</Citation><ArticleIdList><ArticleId IdType="pubmed">16139909</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Policy. 2008 Oct;88(1):110-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18436332</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2009 Mar-Apr;12(2):226-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18671770</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2007 Sep;13(9):1307-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18252100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><noCountry><name sortKey="Beutels, Philippe" sort="Beutels, Philippe" uniqKey="Beutels P" first="Philippe" last="Beutels">Philippe Beutels</name><name sortKey="Edmunds, John W" sort="Edmunds, John W" uniqKey="Edmunds J" first="John W" last="Edmunds">John W. Edmunds</name><name sortKey="Smith, Richard D" sort="Smith, Richard D" uniqKey="Smith R" first="Richard D" last="Smith">Richard D. Smith</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Keogh Brown, Marcus Richard" sort="Keogh Brown, Marcus Richard" uniqKey="Keogh Brown M" first="Marcus Richard" last="Keogh-Brown">Marcus Richard Keogh-Brown</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeBelgiqueV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000069 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000069 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeBelgiqueV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19997956
|texte= The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19997956" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeBelgiqueV4
| This area was generated with Dilib version V0.6.35. |  |